Adam Wright

Adam Wright

Auto-generated profile, based on publicly available information

Adam Wright

Department of Respiratory Sciences, University of Leicester, Leicester, UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2014 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
OEOsama Eltboli
Osama Eltboli
MBMona Bafadhel
Mona Bafadhel
FHFay Hollins
Fay Hollins
AWAdam Wright
Adam Wright
BHBeverley Hargadon
Beverley Hargadon
CBChristopher Brightling
Christopher Brightling
Eosinophilic airway inflammation is observed in 10-30% of COPD subjects. Whether increased eosinophils or impairment in their clearance by macrophages is associated with the severity and frequency of exacerbations is unknown.

28 March 2013 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
AWAdam K. A. Wright
Adam K. A. Wright
MBMathieu Bangert
Mathieu Bangert
JGJenna F. Gritzfeld
Jenna F. Gritzfeld
DFDaniela M. Ferreira
Daniela M. Ferreira
KJKondwani C. Jambo
Kondwani C. Jambo
SGStephen B. Gordon
Stephen B. Gordon
Pneumococcal carriage is both immunising and a pre-requisite for mucosal and systemic disease. Murine models of pneumococcal colonisation show that IL-17A-secreting CD4+ T-cells (Th-17 cells) are essential for clearance of pneumococci from the nasopharynx. Pneumococcal-responding IL-17A-secreting CD4+ T-cells have not been described in the adult human lung and it is unknown whether they can be elicited by carriage and protect the lung from pneumococcal infection. We investigated the direct effect of experimental human pneumococcal nasal carriage (EHPC) on the frequency and phenotype of cognate CD4+ T-cells in broncho-alveolar lavage and blood using multi-parameter flow cytometry. We then examined whether they could augment ex vivo alveolar macrophage killing of pneumococci using an in vitro assay. We showed that human pneumococcal carriage leads to a 17.4-fold (p = 0.007) and 8-fold (p = 0.003) increase in the frequency of cognate IL-17A+ CD4+ T-cells in BAL and blood, respectively. The phenotype with the largest proportion were TNF+/IL-17A+ co-producing CD4+ memory T-cells (p<0.01); IFNγ+ CD4+ memory T-cells were not significantly increased following carriage. Pneumococci could stimulate large amounts of IL-17A protein from BAL cells in the absence of carriage but in the presence of cognate CD4+ memory T-cells, IL-17A protein levels were increased by a further 50%. Further to this we then show that alveolar macrophages, which express IL-17A receptors A and C, showed enhanced killing of opsonised pneumococci when stimulated with rhIL-17A (p = 0.013). Killing negatively correlated with RC (r = −0.9, p = 0.017) but not RA expression. We conclude that human pneumococcal carriage can increase the proportion of lung IL-17A-secreting CD4+ memory T-cells that may enhance innate cellular immunity against pathogenic challenge. These pathways may be utilised to enhance vaccine efficacy to protect the lung against pneumonia. Pneumococcal carriage is an important step in the development of cellular and humoral pneumococcal immunity but paradoxically may lead to mucosal diseases such as pneumonia. The frequency of carriage and pneumonia in young healthy adults is very low despite frequent exposures suggesting the presence of appropriate mucosal defences. Lung mucosal immunity against the pneumococcus is poorly described in humans and lags behind recent advances in our understanding of protective cellular responses in mice. We have therefore developed a method to experimentally induce pneumococcal carriage in healthy adults in order to provide a mechanistic insight into the protective responses elicited at the lung surface. We were able to produce carriage in healthy adults and show that – in the absence of respiratory symptoms or local lung inflammation – pneumococcal-responding (adaptive) cellular responses are increased to a large extent. We also provide evidence of cellular cross-talk between lung sentinels and the pneumococcal-responding adaptive response that may help prevent lung infection in humans. Manipulation of this response may provide novel therapeutic approaches to prevent pneumonia. Furthermore these tools allow better interpretation of defective responses in at risk individuals such as the elderly.

1 October 2024 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
HAHnin Aung
Hnin Aung
RTRonnie Tan
Ronnie Tan
CFCara Flynn
Cara Flynn
PDPip Divall
Pip Divall
AWAdam Wright
Adam Wright
NGNeil J. Greening
Neil J. Greening
Introduction: Sub-optimal inhaler adherence undermines the efficacy of pharmacotherapy in COPD. Digitalised care pathways are increasingly used to improve inhaler-use behaviour remotely. This review investigated the feasibility and impact of remote electronic inhaler adherence monitoring (EIM) and intervention platforms on clinical outcomes in COPD.Methods: A literature search was conducted and studies investigating maintenance inhaler use among people with COPD using digital technology were selected. Pairwise and proportional meta-analyses were employed with heterogeneity assessed using I2statistics. When meta-analysis was not feasible, a narrative synthesis of outcomes was conducted.Results: We included 10 studies including 1432 people with COPD whose maintenance inhaler usage was supported by digital inhalers and apps featuring audiovisual reminders and educational content with or without engagement with healthcare providers (HCPs). Inhaler adherence rate (AR) varied with calculation methods, but an overall suboptimal adherence was observed among people with COPD. HCP-led adherence interventions alongside EIM improved mean AR by 18% (95% CI 9–27)versuspassive EIM only. Enhanced AR may reduce COPD-related healthcare utilisation with little impact on health-related quality of life and exacerbation rate. Despite encountering technical issues among 14% (95% CI 5–23%) of participants, 85% (95% CI 76–94%) found digital platforms convenient to use, while 91% (95% CI 79–100%) perceived inhaler reminders as helpful.Conclusion: Digitalised interventions can enhance maintenance inhaler adherence in COPD but their overall effect on clinical outcomes remains uncertain. Further work is required to tailor interventions to individuals’ adherence behaviour and investigate their longer-term impact.

1 November 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
AWAdam K.A. Wright
Adam K.A. Wright
CWCathryn Weston
Cathryn Weston
BRBatika M.J. Rana
Batika M.J. Rana
CBChristopher E. Brightling
Christopher E. Brightling
DCDavid J. Cousins
David J. Cousins
Group 2 innate lymphoid cells (ILC2s) are upstream regulators of IL-5-dependent\ud eosinophil function in asthma. We’ve shown that ILC2s do not express the IL-5R and thus IL-5R-\ud dependent therapeutic interventions (e.g. Benralizumab) are unlikely to be mediated directly on\ud ILC2s.This work was part funded by (for CEB) Airway Disease Predicting Outcomes\ud through Patient Specific Computational Modelling (AirPROM) project (funded through FP7 EU\ud grant), Wellcome Senior Fellowship, (for DJC) Medical Research Council (MRC) and Asthma UK\ud (Centre Grant: G1000758), from the NIHR Biomedical Research Centre based at Guy's and St\ud Thomas' NHS Foundation Trust and King's College London, an equipment grant from the Midlands\ud Asthma and Allergy Research Association (MAARA) and (for CEB and DJC) the National Institute\ud for Health Research (NIHR) Leicester Respiratory Biomedical Unit. BMJR was funded by an MRC\ud and Asthma UK PhD studentship. This paper presents independent research funded by the NIHR.Peer-reviewedPublisher Versio

6 March 2024 in mAbs
Verified
Journal Article
Open access
MBM. Biddle
M. Biddle
PSP. Stylianou
P. Stylianou
MRM. Rekas
M. Rekas
AWA. Wright
A. Wright
JSJ. Sousa
J. Sousa
HVH.S. Virk
H.S. Virk
Antibodies are one of the most important reagents used in biomedical and fundamental research, used to identify, and quantify proteins, contribute to knowledge of disease mechanisms, and validate drug targets. Yet many antibodies used in research do not recognize their intended target, or recognize additional molecules, compromising the integrity of research findings and leading to waste of resources, lack of reproducibility, failure of research projects, and delays in drug development. Researchers frequently use antibodies without confirming that they perform as intended in their application of interest. Here we argue that the determinants of end-user antibody choice and use are critical, and under-addressed, behavioral drivers of this problem. This interacts with the batch-to-batch variability of these biological reagents, and the paucity of available characterization data for most antibodies, making it more difficult for researchers to choose high quality reagents and perform necessary validation experiments. The open-science company YCharOS works with major antibody manufacturers and knockout cell line producers to characterize antibodies, identifying high-performing renewable antibodies for many targets in neuroscience. This shows the progress that can be made by stakeholders working together. However, their work so far applies to only a tiny fraction of available antibodies. Where characterization data exists, end-users need help to find and use it appropriately. While progress has been made in the context of technical solutions and antibody characterization, we argue that initiatives to make best practice behaviors by researchers more feasible, easy, and rewarding are needed. Global cooperation and coordination between multiple partners and stakeholders will be crucial to address the technical, policy, behavioral, and open data sharing challenges. We offer potential solutions by describing our Only Good Antibodies initiative, a community of researchers and partner organizations working toward the necessary change. We conclude with an open invitation for stakeholders, including researchers, to join our cause.

10 November 2016 in Allergy
Verified
Journal Article
Closed access
PDF file
AWA. K. A. Wright
A. K. A. Wright
CNC. Newby
C. Newby
RHR. A. Hartley
R. A. Hartley
VMV. Mistry
V. Mistry
SGS. Gupta
S. Gupta
CBC. E. Brightling
C. E. Brightling